Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutantIDH-2
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More